DMN:FRA
Diamyd Medical AB
€ ०.०६३
०.००%
(०.००) 1D
नोभेम्बर १९, ०८:०१:५२ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.६३ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.६३ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
BigGo Finance
·
३५ मिनेट पहिले
UBS 2027 Outlook: S&P 500 Base Case at 8,200; AI Capex Stall Could Drag It to 5,500
Business Insider
·
५० मिनेट पहिले
Why Morgan Stanley Says the S&P 500 Is Poised to Jump 18%
The Motley Fool
·
१ घण्टा पहिले
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
FOREX.com
·
५ घण्टा पहिले
S&P 500 Grasps At Support as Surging Hike Odds, Treasury Yields Threaten Larger Turn
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB